Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Announcements
                          • Events
                            • Newsletter
                              • Press photos
                                Video
                                Video: What is HTA?    
                                • Home
                                • News
                                • Announcements

                                Announcements

                                Fotoleiste-1b

                                 

                                Current & archive

                                2149
                                ©Juan Gärtner

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce our three new HSO Fact Sheets.

                                Fact Sheet No. 25 (October 2020)
                                Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)

                                Fact Sheet No. 26 (October 2020)
                                Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)

                                Fact Sheet No. 27 (October 2020)
                                Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)

                                More...

                                Adobestock-329115246-von-mike-fouque-klein8
                                @ Mike Fouque

                                Covid-19: HSS/ Horizon Scanning Living Document (v08 November 2020)

                                The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

                                All work steps are conducted in close international (European) cooperation.

                                Publications: 

                                • Policy Brief No. 002: http://eprints.aihta.at/1234/

                                Contact: Claudia Wild

                                More...

                                Kj
                                ©AungMyo

                                Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria

                                The Austrian child and adolescent psychiatric care landscape is characterised by substantial deficits on the intramural, as well as, on the extramural level. To overcome these supply shortfalls alternative outreach approaches, such as home-treatment, can be introduced to facilitate the reduction of hospitalisations. In this context, the present report aimed to systematically characterise international home-treatment-models considering their effectiveness and safety in the area of child and adolescent psychiatry. In addition, the fundamental challenges of implementing such treatment approaches were examined, taking into account the current Austrian care situation.

                                Publication: AIHTA Project report No. 129: http://eprints.aihta.at/1275/

                                Contact: Sarah Wolf, Nicole Grössmann

                                More...

                                2148
                                ©Juan Gärtner

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce our five new HSO Fact Sheets.

                                Fact Sheet No. 20 (September 2020)
                                Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)

                                Fact Sheet No. 21 (September 2020)
                                Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)

                                Fact Sheet No. 22 (September 2020)
                                Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer

                                Fact Sheet No. 23 (September 2020)
                                Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)

                                Fact Sheet No. 24 (September 2020)
                                Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer

                                More...

                                Adobestock-329115246-von-mike-fouque-klein7
                                @ Mike Fouque

                                Covid-19: HSS/ Horizon Scanning Living Document (v07 October 2020)

                                The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

                                All work steps are conducted in close international (European) cooperation.

                                Publications: 

                                • Policy Brief No. 002: http://eprints.aihta.at/1234/


                                Contact: Claudia Wild

                                More...

                                Adobestock-329115246-von-mike-fouque-klein6
                                ©Mike Fouque

                                Covid-19: HSS/ Horizon Scanning Living Document (v06 September 2020)

                                he establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

                                All work steps are conducted in close international (European) cooperation.

                                Publications: 

                                • Policy Brief No. 002: http://eprints.aihta.at/1234/
                                • EUnetHTA Remdesivir Report


                                Contact: Claudia Wild

                                More...

                                Fotolia-115223963-von-jag-cz
                                ©Jag_cz

                                CAR-T Celltherapies, ATMPs and Gene Therapies in Development, Horizon Scanning

                                It is predicted that by 2022 there will be about 16 "Advanced Therapies Medicinal Products" (ATMPs) on the market, about 2-4 new therapies per year. There are currently 11 ATMPs approved. According to the annual report of the "Alliance of Regenerative Medicine (ARM)", by the end of 2019 more than 1,000 clinical trials worldwide are investigating regenerative/ advanced therapies for various diseases, 94 of which are in phase 3, 591 in phase 2, 60% in oncological indications alone. Among the best known already approved are the CAR-T cell therapies (2 approved in Europe, 1 in the approval process) and gene therapies for spinal muscular atrophy (also 2 approved in Europe, 1 in the approval process). Two Horizon Scanning reports – a cooperation project of AIHTA and Tirol Kliniken - dealt with a look into the near future of further gene therapies.

                                The European Medicines Agency (EMA) classifies ATMPs into three main types: Gene therapeutics and somatic cell therapeutic drugs and tissue engineering products. The two reports should address the questions for which indications CAR-T cell therapies and other ATMPs/gene therapies are in development and by when a marketing authorization is expected. To answer the questions, a systematic search of study registries was performed to identify gene therapies in development and ATMPs, followed by the extraction of data on the identified ongoing clinical trials, complemented by a search of the EMA database of drugs under evaluation to identify those therapies that are expected to be approved soon. Finally, published information on the products, their indication and patient population was collected. The search identified 32 ATMPs in 8 broad indication areas and 13 CAR-T cell therapies in haematological malignancies at an advanced stage of development. 

                                Publications: 

                                • Car-T Cell Therapies, Policy Brief No. 6a: http://eprints.aihta.at/1268/
                                • ATMPs and Gene Therapies, Policy Brief No. 6b: http://eprints.aihta.at/1269/

                                Contact: Claudia Wild

                                More...

                                2147
                                ©Juan Gärtner

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce our four new HSO Fact Sheets.

                                Fact Sheet No. 14 (ad April 2020)
                                Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL)

                                Fact Sheet No. 15 (Juli 2020)
                                Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)

                                Fact Sheet No. 16 (Juli 2020)
                                Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)

                                Fact Sheet No. 17 (Juli 2020)
                                Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)

                                Fact Sheet No. 18 (Juli 2020)
                                Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)

                                Fact Sheet No. 19 (Juli 2020)
                                Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab  for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)

                                More...

                                Adobestock-329115246-von-mike-fouque-klein5
                                ©Mike Fouque

                                Covid-19: HSS/ Horizon Scanning Living Document (v05 August 2020)

                                The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

                                All work steps are conducted in close international (European) cooperation.

                                Publication: Policy Brief No. 002: http://eprints.aihta.at/1234/
                                Contact: Claudia Wild

                                More...

                                2419
                                ©AdobeStock

                                Evaluation of individual medical procedures - Reports 2020

                                We are pleased to introduce our new reports.

                                Decision Support Documents 2020:

                                • DSD 119: Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure’
                                  http://eprints.aihta.at/1254
                                • DSD 120: Intrauterine ultrasound-guided transcervical radiofrequency ablation
                                  http://eprints.aihta.at/1255
                                • DSD 121: Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
                                  http://eprints.aihta.at/1256
                                • DSD 122: Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
                                  http://eprints.aihta.at/1257 DSD 123: Vaskuläre photodynamische Therapie mit Padeliporfin (Tookad® Lösung)
                                  http://eprints.aihta.at/1258
                                • DSD 123: Vaskuläre photodynamische Therapie mit Padeliporfin (Tookad® Lösung)
                                  http://eprints.aihta.at/1258

                                +2 Updates:

                                • DSD 97/2. Update 2020: Leadless pacemaker for right ventricle pacing (Update 2020)
                                  http://eprints.aihta.at/1252
                                • DSD106/Update 2020: Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. 
                                  http://eprints.aihta.at/1253

                                More...

                                « < 1 2 3 4 5 ... > »
                                Displaying results 11 to 20.
                                • News
                                  • Announcements
                                    • Events
                                      • Newsletter
                                        • Press photos
                                        • About us
                                          • Evaluation
                                            • History
                                              • Methods
                                                • Team
                                                  • Shareholder & organization chart
                                                    • Stakeholder involvement
                                                      • Press clippings
                                                      • Research areas
                                                        • Oncology
                                                          • High tech medicine
                                                            • Rehabilitation and occupational therapy
                                                              • Prevention and screening
                                                                • Psychological & psychiatric interventions
                                                                  • Health economics
                                                                    • European collaboration
                                                                      • HTA-methods & steering instruments
                                                                        • Complementary medicine
                                                                        • Research Projects
                                                                          • Synopsis of current research projects
                                                                            • Synopsis of completed research projects
                                                                              • Horizon Scanning in Oncology - Reports and Fact Sheets
                                                                                • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                  • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                    • Evaluation of individual medical procedures - Reports
                                                                                      • All projects in an overview
                                                                                      • Publications
                                                                                        • Repository
                                                                                          • HTA-Newsletter
                                                                                            • Annual Reports
                                                                                            • Search
                                                                                              Netzwerk
                                                                                              • Eunethta
                                                                                              • Ebm
                                                                                              • Inahta
                                                                                              • Dexhelpp
                                                                                              Shareholder
                                                                                              • Bmfg
                                                                                              • Sv
                                                                                              • Wgfond
                                                                                              • Noe
                                                                                              • Ooghfond
                                                                                              • Ghls
                                                                                              • Tirol
                                                                                              • Vorarlberg
                                                                                              • Kghfond
                                                                                              • Ghpf
                                                                                              • Burgef
                                                                                              • Contact
                                                                                                • Imprint
                                                                                                  • Privacy Notice
                                                                                                    • Newsletter
                                                                                                      • Sitemap
                                                                                                        © 2021 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                        • Log in